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Long-term endocrine treatment which results in estrogen deprivation causes chronic
stress associated with a series of uncomfortable symptoms leading not only to a decrease
in quality of life but also to cancer recurrence, which may be mediated primarily through
the enhanced expression of angiogenic factors, as well as a series of inﬂammatory
microenvironmental changes that favor tumor progression. In this study, we designed a
clinical trial and aimed to explore the effects of Sanhuang Decoction (SHD) treatment on
chronic stress, inﬂammatory factors, and breast cancer recovery. A total of 90 patients
with breast cancer who met the inclusion/exclusion criteria were randomly allocated to a
treatment or control group. The treatment group received the standard endocrine
treatment and the traditional Chinese medicine decoction known as SHD. The control
group received the standard endocrine treatment only. The treatment period was 6
months. The modiﬁed Kupperman Menopausal Index, the self-rating anxiety scale, and
the self-rating depression scale were evaluated once per month. The body
microenvironment plasma indices related to chronic stress, such as oxidative and
antioxidative stress markers, inﬂammatory factors, hemorheology, coagulation, lipid and
D-dimer, immunologic functions, tumor biomarkers, and angiogenic factors of the
vascular endothelial growth factor (VEGF) were measured before and after 6 months of
treatment. After treatment for 5 months, the scores in the treatment group decreased to
nearly normal levels and the control group showed no signiﬁcant improvement. After
treatment for 6 months, all indices related to the body microenvironment, as well as the
tumor biomarkers and carcinoembryonic antigen, carbohydrate antigen 153, and
angiogenic factor VEGF levels improved signiﬁcantly to normal levels in the treatment
group. Our primary research showed that treatment with SHD effectively improved the
quality of life of breast cancer patients by facilitating a change in the body
microenvironment that controlled tumor growth and prevented drug resistance.

1

August 2021 | Volume 11 | Article 677939

Feng et al.

Sanhuang Decoction in Breast Cancer

Clinical Trial Registration: Chinese Clinical Trial Registry, identiﬁer ChiCTR-IIR2000041413. Date of registration: 2017-06-07 (retrospective registration).
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NF-E2-related factor 2 (Nrf2), hypoxia-inducible factor 1, and
protein kinase C (11). However, these results are derived from
experimental research and have not yet been veriﬁed by
clinical trials.
Traditional Chinese medicine (TCM) is primarily used as a
complementary alternative medicine. TCM has a history of more
than 2,500 years in China and is built on the view that the body is
a series of functional entities, rather than looking at the ﬁxed
somatic structures that perform the activities. It focuses on
harmonizing the inner environment of the body with its
natural surroundings using tools including herbal medicine,
acupuncture, massage, qigong, and dietary modiﬁcations,
among others, and herbal medicines remain the principal tool
in China (12).
Most breast cancer patients experience symptoms of fatigue,
anxiety, ﬁxed incision pain, loss of appetite, lusterless
complexion, pale tongue, and weak pulse, and they are treated
with long-term endocrine therapy. All of the abovementioned
symptoms are manifestations of stress (13, 14). The TCM
decoction known as Sanhuang Decoction (SHD) is a type of
herbal medicine composed of astragalus, turmeric, and rhubarb,
which are tonic substances that improve the immune system to
relieve fatigue and promote blood circulation (15). SHD is
composed of Dahuang, Huangqi, and Jianghuang. Rhei Radix
et Rhizoma (rhubarb, known as Dahuang in Chinese), belongs to
the genus Rheum L. in the Polygonaceae family, and it is composed
of dried roots and rhizomes, including Rheum palmatum L.,
Rheum tanguticum (Maxim. ex Balf.), and Rheum ofﬁcinale Baill.
Rhubarb plays a role in many pharmacological activities, such as
purgation, anti-inﬂammation, anti-cancer, and hepatoprotection,
and has positive beneﬁts on the gallbladder. Astragali Radix (AR)
(known as Huangqi in Chinese) is one of the most popular herbal
medicines used worldwide. It is the dried root of Astragalus
membranaceus (Fisch.) Bg, or Astragalus membranaceus (Fisch.)
Bge. var., mongholicus (Bge.) Hsiao. This herb possesses tonic,
hepatoprotective, diuretic, and expectorant properties (Chinese
Pharmacopoeia Commission, 2010) (16) and has been shown to
exhibit immunomodulatory, antihyperglycemic, anti-inﬂammatory,
antioxidant, and antiviral activities, among others. Traditionally, it
has been used to treat weakness, wounds, anemia, fever, multiple
allergies, chronic fatigue, loss of appetite, uterine bleeding, and
uterine prolapse. The rhizome of Curcuma Longa, turmeric
(Jianghuang in Chinese), is used as a Chinese medicine which can
expel gas line and pass through the pain, and the selected
prescription takes the power of fried astragalus to invigorate qi,
which helps rhubarb to activate blood circulation and turmeric to
push qi. When qi is sufﬁcient, it increases movement and removes
dampness and stasis. It can relieve dyspnea, hypodynamia, and
spontaneous perspiration, as well as alleviating symptoms, such as
cumbrous, anesthesia caused by phlegm, dampness, and blood

INTRODUCTION
Breast cancer is the most common cancer among Chinese
women (1). Breast cancer treatments have evolved over the last
40 years from profound and aggressive to conservative
procedures that minimize tissue trauma and physical
deformity. This is because the overall survival has improved
with developments in surgery, chemotherapy, radiotherapy,
target therapy, endocrine therapy, and so on. Among these, the
endocrine treatment lasting 5–10 years is usually considered the
standard choice for patients with estrogen receptor-positive
cancers for 5 or 10 years (2, 3). However, such a long period of
estrogen deprivation caused by the administration of selective
estrogen receptor modulators or aromatase inhibitors results in
chronic stress with symptoms of anxiety, poor appetite, difﬁculty
falling asleep, and arthralgia syndrome; all of which not only lead
to a decrease in the quality of life but also induce the recurrence
of cancer (4). Studies have reported that chronic stress can alter
immunological, neurochemical, and endocrine functions leading
to cancer progression, which may be mediated primarily through
the activation of the tumor cell phosphoinositide 3‐kinase
(PI3K) signaling pathway. This results in a markedly increased
vascularization and an enhanced expression of the vascular
endothelial growth factor (VEGF), matrix metalloproteinase
(MMP)-2, and MMP-9 (5, 6).
When exposed to stress over a long period of time, people
produce a series of inﬂammatory microenvironmental changes
that favor tumor progression (7). Studies have demonstrated
that oxidative stress increases the levels of proinﬂammatory
cytokines, such as tumor necrosis factor (TNF)-a and
interleukin-6 (IL-6), and upregulates inﬂammatory molecules,
such as vascular cell adhesion molecule-1, intercellular adhesion
molecule-1, and nuclear factor-kappa B (NF-кB); all of which
contribute to tumor growth, migration, and metastasis (8).
Researchers have reported many different effects of acute and
chronic oxidative stress on tumor growth. One study showed
that the growth of estrogen receptor-positive breast cancer cells
(MCF-7) was inhibited during acute exposure to an oxidative
stress environment, whereas exposure to such a sustained
chronic environment over a period of 3 months promoted a
signiﬁcant growth. The researchers further analyzed the related
gene expression and found an upregulation of the pro-metastatic
genes, VEGF, WNT1, and cluster of differentiation 44 (CD44),
and a downregulation of the anti-metastatic gene E-cadherin was
observed in cells under persistent exposure to oxidative stress for
3 months (9, 10). Studies have also suggested that while tumor
cells adapted to the long-term reactive oxygen species (ROS)induced toxicity, this promoted acquired multidrug resistance in
breast cancer cells through the PI3K/protein kinase B (PI3K/Akt)
and NF-ĸB pathways regulated by the stress-related factors,
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stasis. In China, SHD has been applied in clinical trials to treat
breast cancer in combination with chemotherapeutic drugs (17–22).
Our previous clinical research results showed that SHD could not
only ameliorate the symptoms but also the serological
microenvironments of stress during the perioperative period. In
our previous studies, we found that SHD reduces oxidative stress
and suppresses tumor angiogenesis by inhibiting the PI3K and
aurora kinase signaling pathways. We also demonstrated the
synergetic and anti-resistant effects of SHD with endocrine
therapy on breast cancer (23). Therefore, it is reasonable to
further explore the potential effects of SHD on chronic stress with
long-term endocrine therapy.
Numerous clinical trials have focused on controlling chronic
stress in breast cancer patients with a series of psychological
interventions and comprehensive lifestyle changes, such as
prescribed exercise programs, mindfulness-based stress
reduction, and bioactive natural dietary supplements. Primary
conclusions have revealed that patients beneﬁt from a positive
attitude toward chronic stress, leading to relief of insomnia,
anxiety, and fatigue with an enhanced quality of life (24). It was
previously reported that psychological interventions could
signiﬁcantly reduce the risk of breast cancer recurrence and
death from breast cancer (P = 0.034 and P = 0.016, respectively)
(25). However, such trials focused on the improvement of the
subjective feelings of the patient and did not report on any
objective evaluations related to tumor changes.
Several studies have suggested that oxidative stress, chronic
inﬂammation, and cancer are closely linked. Studies have found
that long-term stress generated ROS that recruit inﬂammatory
cells and stimulate tumor progression and recurrence (26).
Therefore, in this study, we designed a clinical trial and aimed
to explore the effects of SHD treatment on chronic stress,
inﬂammatory factors, and breast cancer recovery.

detection); and 3) underwent more than 6 months of
endocrine treatment. Patients were excluded if they had:
1) inﬂammatory breast cancer; 2) central nervous system
metastases; 3) symptomatic visceral disease; 4) clinically
signiﬁcant, uncontrolled heart disease; or 5) a cardiac
repolarization abnormality, including a QT interval corrected
for heart rate according to Frederica’s formula greater than 450
ms; 6) recurrence or metastasis diagnosed by imaging or
histology;7) participating in other clinical trials; and 8) in
pregnancy or lactation or accompanied by severe diabetes.
If a patient withdrew consent, failed to adhere to the research
protocol, or experienced a serious adverse event, they were
recorded as withdrawn and not included in the analysis.
Written informed consent was obtained from all the enrolled
patients. The trial was performed in accordance with the Good
Clinical Practice guidelines and the Declaration of Helsinki. The
study protocol and any amendments were approved by an
independent ethics committee or institutional review board at
each site (IRB application receipt 2017NL-007-03). A study
steering committee comprising participating international
investigators and Novartis representatives oversaw the
execution of the trial. An independent data monitoring
committee assessed the safety data.

Study Design
Ninety female patients were randomly and prospectively
assigned (1:1) to the treatment group or control group by
permuted block randomization through interactive response
technology. At enrolment, investigators registered patients in
the interactive response technology system with their identifying
information, and then, the patients were assigned a seven-digit
number that was retained throughout their participation in the
study to facilitate anonymity. All patients, and investigators
administering treatment, assessing outcomes, and analyzing
data were masked to the treatment group assignment. Masking
to group assignment was ensured with the use of matching
placebos with identical packaging, labeling, schedule of
administration, and appearance. The sponsor was masked to
the randomized treatment group allocation.

METHODS
Methods and Study Protocol
The research protocol was approved by the Institutional Review
Board of Human Research at the Afﬁliated Hospital of Nanjing
University of Traditional Chinese Medicine. Ninety patients
from the Department of Breast Diseases, Jiangsu Provincial
Hospital of TCM, were identiﬁed, screened, and enrolled in the
study between June 2017 and December 2018, and all patients
provided an informed consent.

Intervention
All patients were treated with the standard endocrine treatment
with or without ovarian function suppression according to the
breast cancer guidelines of the Chinese Society of Clinical
Oncology. In the treatment group, the patients received 100
mL of SHD solution twice daily for six consecutive months.
SHD containing 30 g of Astragalus membranaceus (TCM
name: Huang qi), 10 g of Rheum ofﬁcinale (TCM name:
Dahuang), and 10 g of Curcuma Longa (TCM name:
Jianghuang) were acquired from Jiangsu Province Hospital of
TCM (Nanjing, China). The total weight of the crude herb was
50 g. The herbs were blended in 400 mL of double-distilled water
(1:8, w/v) for 1 h and heated to 100°C for 2 h. After continuous
boiling for 2 h, the remainder of the sample was condensed to
200 mL. The dose was equated to 200 mL SHD daily for an
average adult with a body weight of 60 kg. The preparatory steps

Inclusion/Exclusion Criteria
Patients in this study were recruited from a population of
patients undergoing endocrine treatment and were invited to
participate in the study if they fulﬁlled all of the following
criteria: 1) a diagnosis of breast cancer with planned modiﬁed
radical surgery and 2) between the ages of 30 and 70 years.
Patients were included in the study if they: 1) provided informed
consent; 2) showed estrogen receptor and/or progesterone
receptor positivity (by pathological immunohistochemical
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Diagnostics GmbH, Mannheim, Germany]; AU5800 [Beckman
Coulter, Fullerton, CA, USA]; ZL9600C [Beijing Zhongchi
Weiye Technology Development Co., Ltd., Beijing, China]).
Serum levels of CD3, CD4, CD8, CD4/CD8, and
immunoglobulin (Ig) G, IgA, IgM, complement 3 (C3), and
complement 4 (C4) were detected using a ﬂow cytometry
analyzer (FACS Canto II [BD Biosciences, San Jose, CA, USA];
Immage 800 [Beckman Coulter]).

were completed using a Tisanes device at Jiangsu Province
Hospital of TCM. The ﬁnal 200 mL decoction was
administered orally as a split dose twice daily during the entire
clinical research period.

Outcome Measures
Measurement Scales
Clinical symptoms focused on chronic stress were measured and
recorded once a month for 6 months.
A modiﬁed Kupperman Menopausal Index (KMI) was used
to measure the quality of life induced by the endocrine
treatments. The modiﬁed KMI assesses the degree of
symptoms, such as hot ﬂushes, sweats, abnormal tactile
sensations, insomnia, impatience and ease of irritability,
emotional depression, dizziness, fatigue, and aching extremities.
The self-rating anxiety scale (SAS) and self-rating depression
scale (SDS) were administered during the endocrine treatment.
The SAS and SDS were applied to evaluate the effects of chronic
clinical stress in terms of symptoms related to anxiety and
depression, respectively.

Biomarkers
Tumor biomarkers and angiogenic factors of VEGF were
evaluated in relation to tumor growth using an ELISA (EK18396; Lianke Biological Company, Hangzhou, China).
Serum levels of carbohydrate antigen 153 (CA153), CA125,
and carcinoembryonic antigen (CEA) were measured using an
access immunoassay analyzer (Unicel Dxi800 [Beckman
Coulter]; ARCHITECT i2000 SR [Abbott, Abbott Park,
IL, USA]).

Statistical Analysis
The results were analyzed using the SPSS 18.0 (IBM, Armonk,
NY, USA). Continuous data were evaluated with a t-test, graded
data with a Ridit analysis, and categorical data with an X2 test.
Statistical signiﬁcance was set at P < 0.05.

Laboratory Data
Laboratory data were collected for the evaluation of the body
microenvironment under chronic stress during the
endocrine treatment.
Oxidative and antioxidative stress markers in plasma were
measured. Blood samples (5 mL of blood was collected, and
blood extracts and sera were prepared for analysis). Serum nitric
oxide (NO) (No. A012-1-2; Nanjing Jiancheng Company,
Nanjing, China), superoxide dismutase (SOD) (No. A001-3-2;
Nanjing Jiancheng Company), malondialdehyde (MDA) (No.
A003-1-2; Nanjing Jiancheng Company), glutathione peroxidase
(GSH-px) (No. A005-1-2; Nanjing Jiancheng Company), and
total antioxidant capacity (TAOC) (No. A015-1-2; Nanjing
Jiancheng Company) were measured using a Shimadzu
spectrophotometer (Shimadzu Company, Kyoto, Japan).
According to the operational instructions, the absorbance value
was measured at 550 nm based on a comparison with the
standard curve, and the NO and SOD contents were calculated.
Serum levels of TNF-a, IL-6, and IL-8 were evaluated using
enzyme-linked immunosorbent assay (ELISA) kits purchased
from Beijing 4A Biotech Co., Ltd. (Beijing, China) (Nos.
20150109 and 20150113).
Hemorheology testing, which included whole blood viscosity,
plasma viscosity, hematocrit, the erythrocyte aggregation index,
and the erythrocyte rigidity index, was undertaken using a blood
viscometer (LBY-N6; Beijing Prisheng Instrument Co., Ltd.,
Beijing, China) with a fasting blood sample. Blood coagulation
measures, including prothrombin time, activated partial
thrombin time, thrombin time, plasma ﬁbrinogen levels, and
D-dimer levels, were measured using an automatic coagulation
analyzer (CA-1500; SYSMEX CORPORATION, Kobe, Japan).
Lipid indices, including triglyceride (TG), total cholesterol (TC),
low-density lipoprotein cholesterol (LDL-C), high-density
lipoprotein cholesterol (HDL-C), apolipoprotein-A (apo-A),
and apolipoprotein-B (apo-B) levels, were assessed using an
automatic biochemical immunity analyzer (Cobas 8000 [Roche

Frontiers in Oncology | www.frontiersin.org

RESULTS
Patient Recruitment and Characteristics
A total of 108 patients were assessed for eligibility, and 90 were
enrolled in the study between June 2017 and December 2018. A
study ﬂow chart is shown in Figure 1. Patients were randomly
divided into two groups. There were no statistically signiﬁcant
differences between the two groups in terms of age, clinical stage,
modus operandi, types of endocrine treatment, the duration of
treatment, and the drugs used for endocrine treatment (Table 1).

Clinical Symptoms Measured by the
Modiﬁed KMI, SAS, and SDS
Our primary results showed that the patients in both groups
experienced a moderate degree of menopausal symptoms with an
average KMI score of approximately 33. After treatment for 5
months, the scores in the treatment group decreased to 13.98,
indicating near-normal scores. However, the patients in the
control group still presented with moderate stress without any
improvements. A score of 50–59 indicated a mild state of anxiety
on the SAS. We found that the scores in the treatment group
decreased to 45.98 after only 2 months of treatment, which
means that patients were more or less free of anxiety. In
comparison, the control group demonstrated a continuous
state of moderate anxiety until the end of the clinical trial. In
China, an SDS score of more than 50 normally indicates a state of
depression (Table 2). Therefore, our results showed that all
patients in the control group experienced a relatively serious
depression during the whole trial period; however, the patients in
the treatment group recovered completely on the ﬁfth month of
SHD treatment with scores decreasing to 32.20. Statistical
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FIGURE 1 | Participant ﬂow chart.

differences were observed between the two groups after only 1
month of treatment as shown in Figure 2.

TABLE 1 | Baseline of the subjects.
Index

Experiment
group

Control
group

P-value

Age (year)
Sex
TNM staging (n)
T1N0M0
T2N0M0
T1N1M0
T2N1M0
modus operandi
Simple mastectomy with sentinel
lymph node biopsy
Radical modiﬁed mastectomy
Kinds of endocrine treatment
Tamoxifen
Letrozole
Anastrozole
Exemestane
Duration of endocrine treatment
Half to one year
One to one half year
One half to two years

53.8 ± 7.04
Female (45)

51.85 ± 7.84
Female (45)

0.548
–
0.963

15
18
6
6

18
18
6
3

30

35

15

10

15
12
12
6

18
9
12
6

18
21
6

21
15
9
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Laboratory Data Results
Patients in the control group who only received endocrine
therapy for 6 months showed stable or increased NO and
MDA levels, slight decreases in the anti-stress factor, SOD, and
stable levels of TAOC and GSH-PX (Table 3). In contrast, the
patients in the treatment group showed stress-promoting factor
levels that had decreased to approximately 30% to 50% and antistress factor levels that had increased between 50% and 200%.
Signiﬁcant differences were observed between the two groups.
Detailed data are shown in Figure 3.
As shown in Figure 4, TNF-a, IL-6, and IL-8 were
signiﬁcantly reduced after 6 months in the SHD group, but not
in the control group, and this indicated that SHD can
signiﬁcantly improve the inﬂammatory response of patients
with breast cancer treated with endocrine therapy. The
hemorheology study showed that low cut whole blood viscosity
(1/S), medium cut whole blood viscosity (30/S), and high cut

0.755

0.855

0.724
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TABLE 2 | Kupperman as well as SAS and SDS scores changes during clinical trial for 6 months (n=45 each group).
Groups
Treatment
Control
Treatment
Control
Treatment
Control

Indices

Start

1 month

2 months

3 months

4 months

5 months

6 months

Kupperman Scores

33.14 ± 3.28
32.98 ± 3.16
0.26
58.32 ± 5.96
58.43 ± 5.78
0.83
65.73 ± 6.39
66.12 ± 5.87
0.59

25.08 ± 1.65
33.59 ± 2.75
0.04
50.76 ± 4.65
57.87 ± 6.42
0.04
61.34 ± 5.48
65.87 ± 6.52
0.04

22.31 ± 1.95
31.52 ± 3.04
0.03
45.98 ± 5.37
58.72 ± 4.76
0.02
56.45 ± 6.32
66.37 ± 5.84
0.03

20.18 ± 2.13
34.18 ± 1.78
0.00
43.37 ± 6.12
61.03 ± 5.18
0.00
48.42 ± 5.72
67.18 ± 6.34
0.00

15.41 ± 1.57
33.63 ± 1.98
0.00
36.75 ± 5.18
62.72 ± 6.32
0.00
40.38 ± 6.59
68.92 ± 6.18
0.00

13.98 ± 2.34
32.57 ± 2.84
0.00
30.91 ± 6.45
61.97 ± 6.18
0.00
32.20 ± 7.03
66.98 ± 7.02
0.00

10.87 ± 3.02
33.77 ± 3.45
0.00
28.72 ± 5.83
63.67 ± 5.89
0.00
30.18 ± 6.52
67.13 ± 6.98
0.00

P value
SAS
P value
SDS
P value

FIGURE 2 | Clinical Symptoms. Measured by the Modiﬁed KMI, SAS, and SDS After 5 months of treatment, the KMI score of the treatment group decreased to
13.98, which was close to normal; In the treatment group, the SAS score decreased to 45.98 points after 2 months of treatment, indicating that patients had more
or less got rid of anxiety; An SDS score of more than 50 usually indicates a depressive state, while patients in the treatment group fully recovered after 5 months of
SHD treatment, with their score dropping to 32.20.

TABLE 3 | Changes of stress related serum factors during 6 months of treatment (n=45 each group).
Groups

NO (umol/L)

SOD (u/ml)

Start

6 months

Start

Treatment
Control
P value

56.42 ± 2.31
57.42 ± 3.28
0.15

27.39 ± 2.14
48.73 ± 2.89
0.00

73.45 ± 4.63
74.48 ± 3.97
0.91

Groups

MDA (nmol/L)
Start
6 months
11.25 ± 0.32
4.36 ± 0.47
10.98 ± 0.41
12.37 ± 0.25
0.004
0.00

Start
0.24 ± 0.09
0.25 ± 0.09
0.95

Treatment
Control
P value

6 months
127.59 ± 7.52
56.42 ± 2.92
0.00

Start

6 months

32.81 ± 3.51
34.05 ± 2.8
0.23

72.43 ± 3.46
42.07 ± 2.45
0.00

TAOC (u/ml)

whole blood viscosity (200/S) were signiﬁcantly reduced compared
with the control group. The largest signiﬁcant difference was for
high cut whole blood viscosity (200/S). Similarly, the study of
plasma and whole blood viscosity showed that plasma viscosity,
whole blood viscosity (high cut), and whole blood viscosity (low
cut) were signiﬁcantly reduced compared with the control group,
with plasma viscosity being most signiﬁcantly reduced (Figure 5).
The results of the blood lipid study showed that TG, TC, and LDL
levels decreased signiﬁcantly in the treatment group, but HDL
levels increased signiﬁcantly (Figure 6). In the study of immune
factors, it was found that the immune factors CD8 and C3 were not
statistically signiﬁcant compared with the control group after 6
months of SHD treatment (Table 4). However, the indices of
tumor cell proliferation inhibition (CD3, CD4, CD4/CD8, IgM,
IgA, IgG, and C4) were signiﬁcantly improved after 6 months of
SHD treatment, and CD4/CD8 had improved compared with the
control group (Figure 7).

Frontiers in Oncology | www.frontiersin.org

GSH-PX (pmol/ml)

6 months
0.34 ± 0.04
0.23 ± 0.12
0.00

Biomarkers
A summary of the ﬁndings of the tumor growth-related
biomarkers at baseline and after 6 months of SHD treatment is
presented in Table 5. VEGF, CA153, and CEA levels decreased
signiﬁcantly after 6 months of SHD treatment (P < 0.01),
illustrating that endocrine treatment combined with SHD can
signiﬁcantly improve the curative effect and may provide a better
prognosis for patients with breast cancer. But, CA125 had a nonstatistical signiﬁcance (Figure 8).

DISCUSSIONS
Our results showed a statistically signiﬁcant improvement in all
three scores after only 1 month of oral administration of SHD.
However, after treatment for 6 months, the KMI score was
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FIGURE 3 | Antioxidant Indices. Patients in the control group showed stable or increased NO and MDA levels, slight decreases in the anti-stress factor, SOD, and
stable levels of TAOC and GSH-PX. While the treatment group showed stress-promoting factor levels that had decreased to approximately 30% to 50% and antistress factor levels that had increased between 50% and 200%. (ns mean non-statistics signiﬁcance **P ≤ 0.005; ***P ≤ 0.001).

lifestyle and emotions, such as worry and fear, may have a
positive inﬂuence on the prognosis of breast cancer (27, 28).
However, here, we report relief from chronic stress caused by
long-term endocrine treatment with the use of oral SHD, which
facilitates a positive change in the tumor microenvironment.
At baseline, nearly 70% of the patients recruited in the study
were in the early stage of breast cancer with no lymph node

reduced to one-third of the baseline scores before treatment,
while the scores of SDS and SAS reduced to half of the baseline
scores. It has been reported that the KMI score could be reduced
by 63% with estrogen replacement treatment without increasing
the risk of recurrence in the short-term. Our results achieved
effects comparable to that of estrogen replacement treatment,
with a decrease of 67%. Some clinical trials have reported that
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FIGURE 4 | Inﬂammatory Factors. Compared with the control group, TNF-a, IL-6, and IL-8 were signiﬁcantly reduced after 6 months in the SHD group. (ns mean
non-statistics signiﬁcance **P ≤ 0.005; ***P ≤ 0.001).

FIGURE 5 | Hemorheology Study. The study of plasma and whole blood viscosity showed that plasma viscosity, whole blood viscosity (high cut), and whole blood
viscosity (low cut) were signiﬁcantly reduced compared with the control group, with plasma viscosity being most signiﬁcantly reduced. (ns mean non-statistics
signiﬁcance **P ≤ 0.005; ***P ≤ 0.001).

This made it easy for patients to administer SHD, thereby
enhancing compliance to ensure clinical effects.
Due to the health care insurance policies in China, patients
only receive 1 month of medication at a time and have to attend
the hospital once a month for the next. Therefore, it was
convenient for us to evaluate the KMI, SDS, and SAS once
a month.
The KMI, SAS, and SDS scores provide information about the
multiple dimensions of the status of patients during endocrine
treatment. Previous studies have reported that symptoms of
depression and anxiety remain unchanged throughout the
course of endocrine treatment (29). Our results for the control
group showed similar results, indicating that patients may
experience continual chronic stress; however, we also showed

metastasis. Therefore, it was expected that they would have a
long lifespan and a normal lifestyle. Moreover, they may have
had a high demand for the quality of life and paid more attention
to the feeling of being unwell. More than 90% of patients started
endocrine treatment within one and a half years, which meant
that the uncomfortable feelings, such as gastrointestinal reaction,
irregular menstruation, et al., may be the result of the sudden
adaptation to endocrine treatment within a short period of time.
In contrast to most clinical studies, which have applied
psychological regulation interventions, such as mindfulness,
self-education, or anti-oxidative food intake to relieve chronic
stress, we employed a TCM decoction. The hospital pharmacy
posted a drug-decocting machine directly to the home address of
the patient, along with standard boiling procedure instructions.
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FIGURE 6 | Blood Lipid Study. TG, TC, and LDL levels decreased signiﬁcantly in the treatment group, but HDL levels increased signiﬁcantly. (ns mean non-statistics
signiﬁcance **P ≤ 0.005; ***P ≤ 0.001).

In addition, when patients are treated with long-term endocrine
therapy, resistance to endocrine therapy may be mediated in part
by ROS-mediated dysregulation of redox-sensitive signaling
pathways (34). Our results also showed that the sera of patients
who received endocrine treatment for 6 months was not able to
inhibit the growth of tamoxifen-resistant cells, while such sera
could acquire this inhibitory ability with a decrease in chronic
stress through the administration of oral SHD.
Many factors are closely related to chronic stress. Extensive
research during the last two decades has revealed the mechanism
by which continued oxidative stress can lead to chronic
inﬂammation (35). There are reports that chronic stress could
induce a microenvironment with an enhanced expression of
inﬂammatory factors, such as TNF-a, IL-1, IL-6, and IL-8, which
are believed to play a role in malignant tumor progression and
negative prognosis in cancers, including breast cancer (36, 37). It
was previously reported in a clinical trial that breast cancer
patients may enjoy a good prognosis by reducing the serum
levels of inﬂammatory factors IL-6, IL-8, and TNF-a, and this
might even offer protection from the metastases and recurrence
of breast cancer (38). Our results showed that the serum

that this condition could be relieved with TCM treatment in
1 month.
Studies have shown that uncomfortable feelings experienced
during endocrine treatment are closely related to chronic stress
(30, 31). It was reported that variations in experience were
related to emotional distress in women undergoing endocrine
treatment, suggesting the importance of including an assessment
of chronic stress to fully understand the extent of stressdepression relationships and the underlying mechanisms.
Thus, we evaluated the serum changes related to oxidative and
anti-oxidative stress during 6 months of endocrine treatment. In
accordance with the amelioration of emotional state and quality
of life, the serum indices related to stress improved signiﬁcantly
after treatment with SHD.
Long-term chronic stress in breast cancer patients has been
reported to be closely related to the progress, metastasis, and
prognosis of such patients (32). Mechanical research has shown
that stress increases therapy resistance through epithelialmesenchymal transition markers and promotes lung metastatic
colonization of circulating breast cancer cells by creating a premetastatic niche by activating b-adrenergic signaling (33).
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TABLE 4 | Change levels of inﬂammatory factors,hemorheology,lipid and immunologic factors in vivo (n=45 each group).
Groups

Inﬂammatory factors
TNF- (ng/ml)

Treatment
Control
P value

IL-6 (mmol/L)

Start

6 months

Start

6 months

Start

6 months

12.31 ± 3.1
12.85 ± 2.8
0.76

3.48 ± 1.12
15.78 ± 2.93
0.00

107.39 ± 31.02
106.91 ± 18.40
1.00

62.71 ± 39.47
103.54 ± 22.74
0.00

112.92 ± 81.66
111.74 ± 54.83
1.00

61.67 ± 31.94
114.58 ± 89.43
0.00

Groups

Treatment
Control
P value

Low cut whole blood viscosity (1/S)
Start
6 months
17.55 ± 1.5
16.28 ± 1.49
17.65 ± 1.74
17.86 ± 1.68
1.00
0.00

Groups

Treatment
Control
P value

plasma viscosity
Start
6 months
1.55 ± 0.14
1.39 ± 0.11
1.55 ± 0.11
1.57 ± 0.1
0.99
0.000

Groups
TC
Treatment
Control
P value
Groups

Treatment
Control
P value

Start
5.05 ± 0.6
4.91 ± 0.67
0.72

6 months
4.48 ± 0.57
4.96 ± 0.67
0.002

Lipid indices (mmol/L)
HDL
Start
6 months
1.57 ± 0.16
1.71 ± 0.15
1.55 ± 0.14
1.52 ± 0.17
0.93
0.00

Groups

Hemorheological indices (mPa.s)
Medium cut whole blood viscosity (30/S)
Start
6 months
4.83 ± 0.13
4.66 ± 0.21
4.81 ± 0.18
4.86 ± 0.19
0.95
0.00
Hemorheological indices (mPa.s)
Reduced viscosity of whole blood (high cut)
Start
6 months
5.53 ± 0.39
5.37 ± 0.21
5.53 ± 0.38
5.61 ± 0.41
0.99
0.009
Lipid indices (mmol/L)
TG
Start
6 months
2.75 ± 0.54
1.55 ± 0.21
2.66 ± 0.56
2.82 ± 0.39
0.78
0.000

Start
24.06 ± 7.85
24.47 ± 7.42
0.99

Groups

Start
59.94 ± 6.85
60.6 ± 6.91
0.97

Start
1.72 ± 0.69
1.81 ± 1.22
0.96

Groups

Treatment
Control
P value

Start
1.73 ± 0.43
1.73 ± 0.48
0.99

6 months
2.84 ± 0.26
3.19 ± 0.26
0.00
CD4

Start
36.29 ± 7.59
36.33 ± 8.51
0.99

6 months
1.91 ± 0.73
1.38 ± 0.56
0.016

B cell immunologic indices
IgM (g/L)
Start
6 months
1.08 ± 0.39
1.39 ± 0.43
1.06 ± 0.3
1.09 ± 0.37
0.99
0.001

6 months
12.25 ± 1.55
11.04 ± 1.62
0.002

Complement indices (ng/ml)
C3
Start
6 months
0.88 ± 0.15
0.93 ± 0.16
0.89 ± 0.14
0.88 ± 0.14
0.99
0.38

IgG
6 months
2.17 ± 0.47
1.8 ± 0.45
0.001

LDL
Start
3.17 ± 0.29
3.13 ± 0.34
0.91

6 months
64.47 ± 6.00
59.2 ± 6.81
0.001

B cell immunologic indices (g/L)
IgA

Treatment
Control
P value

Reduced viscosity of whole blood (low cut)
Start
6 months
41.43 ± 4.06
39.39 ± 3.75
41.94 ± 3.95
42.18 ± 3.95
0.93
0.005

T cell immunologic indices (%)

CD4/CD8
6 months
23.18 ± 7.64
25.47 ± 7.16
0.47

High cut whole blood viscosity (200/S)
Start
6 months
3.94 ± 0.12
3.67 ± 0.21
3.92 ± 0.15
3.99 ± 0.16
0.94
0.00

CD3

T cell immunologic indices (%)
CD8

Treatment
Control
P value

IL-8 (mmol/L)

Start
10.91 ± 1.46
10.85 ± 1.6
0.99

6 months
39.59 ± 6.36
32.13 ± 6.61
0.00

Complement indices (ng/ml)
C4
Start
6 months
0.22 ± 0.05
0.27 ± 0.06
0.22 ± 0.06
0.23 ± 0.06
0.99
0.007

hypercholesterolemia, which ultimately leads not only to high
risk of cardiovascular disease but also an even higher risk of
mortality. It was reported that the addition of blood lipid control
treatment would effectively improve the disease-free survival in
such patients (38). Our research showed that treatment with
TCM cannot only improve the quality of life during endocrine
treatment but also reduce the serum levels of blood lipids, thus
producing a favorable environment for body recovery and relief
from the side effects of endocrine treatment simultaneously.

levels of such factors could be reduced to approximately 30%
to 50% of baseline levels in breast cancer patients treated
with SHD for chronic stress. Our results remind us that a
continued interference with the state of stress may provide a
preferred inﬂammatory microenvironment for tumor growth
and progression.
It has been reported that long-term continued endocrine
treatment, which results in estrogen deprivation and loss
of its protective function, results in a high incidence of
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FIGURE 7 | Immune Factors. The immune factor (CD8, and C3) was not statistically signiﬁcant compared with the control group after 6 months of SHD treatment;
The indices of tumor cell proliferation inhibition (CD3, CD4, IgM, IgA, IgG and C4) were signiﬁcantly improved after 6 months of SHD treatment. CD4/CD8 had
improved compared with the control group. (ns mean non-statistics signiﬁcance *P ≤ 0.05; **P ≤ 0.005; ***P ≤ 0.001).

TABLE 5 | Changes of VEGF,CA153,CA125 and CEA.
Groups

VEGF (pg/ml)
Start

Treatment
Control
P value
Groups
Treatment
Control
P value

CA153 (u/ml)
6 months

37.28 ± 10.34
15.14 ± 5.25
38.14 ± 9.47
50.43 ± 6.82
0.96
0.00
CEA (ng/ml)
Start
6 months
1.85 ± 1.21
1.06 ± 1.09
1.90 ± 1.08
2.43 ± 1.50
1.00
0.00

Start

6 months

Start

6 months

35.28 ± 1.92
34.96 ± 2.34
0.83

23.08 ± 0.57
32.54 ± 1.87
0.00

14.12 ± 5.05
14.40 ± 5.67
0.99

11.75 ± 4.49
14.00 ± 6.41
0.21

endocrine treatment and signiﬁcantly downregulate the tumor
growth markers, VEGF and CEA.
Research suggests that higher levels of bodily stress can
predict patient relapse in high-risk ER(+) breast cancer
patients receiving endocrine therapy (39). Moreover,
mitochondrial markers, which represent the oxidative stress
state of the body, are closely related to tumor recurrence,
metastasis, and tamoxifen resistance (40). Extensive research
over the last two decades has suggested that oxidative stress,
chronic inﬂammation, and cancer are closely linked.

Since research has reported that cellular and humoral
immunodeﬁciency, which may be caused by stress and depression
in breast cancer patients, could produce resistance to hormone
therapy and often correlates with a poor prognosis, we checked
these indices during the 6-month endocrine treatment period and
found that CD4 was inhibited and the tumor growth markers,
VEGF and CEA, levels improved. The results are partly in
accordance with those of other reports that showed signiﬁcantly
increased plasma VEGF levels. Our results revealed that SHD could
effectively regulate the cellular and humoral immunity state during
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FIGURE 8 | Tumor Biomarkers VEGF, CA153, and CEA levels decreased signiﬁcantly after 6 months of SHD treatment, but CA125 had non-statistics signiﬁcance.
(ns mean non-statistics signiﬁcance ***P ≤ 0.001).

psychological stress due to the deformed chest shape with one
breast missing. Furthermore, 6 months of endocrine treatment
would produce additional discomfort, which may exacerbate the
stress even further. Such factors experienced together could have a
moderate inﬂuence on the responses of the patients on the KMI, as
well as the SAS and SDS, and these symptoms would not have been
relieved if treatment measurements had not been undertaken.
In summary, our clinical research showed that the chronic
stress state could be effectively relieved with SHD treatment by
controlling the tumor microenvironment with amelioration of
chronic oxidative stress in the body. SHD does this via the
regulation of stress-related factors, as well as inﬂammatory,
hemorheology, lipid, immune, and angiogenic factors; all of
which function to promote tumor growth or drug resistance.
SHD treatment was also associated with a signiﬁcantly improved
quality of life, with the patients mainly presenting with optimistic
attitudes toward the disease and daily life and a relatively
cheerful mood. After 6 months of observation, some tumor
biomarkers decreased and this inhibited the growth of

Several inﬂammatory mediators, such as TNF-a, IL-6, TGF-b,
and IL-10, have been shown to play a role in cancer progression
(41). In this study, we explored the levels of some of these
cytokines in the tumor microenvironments in terms of their
capacity to generate reactive oxygen and nitrogen species, and
their potential involvement in the mechanisms of angiogenesis
and drug resistance. As previously reported, SHD downregulates
aurora kinase A to inhibit breast cancer cell growth and
ameliorate inﬂammatory status in breast cancer patients during
the perioperative period. In addition, emodin, as the main
ingredient of SHD, inhibits the bioactivity of tamoxifenresistant breast cancer cells by inhibiting the PI3K pathway
and inhibiting angiogenesis.
However, there had been some limitations in our research. The
patients included in our clinical trial had an average age of 51–53
years, and most would have been experiencing perimenopause and
possibly discomfort induced by a signiﬁcant estrogen reduction. In
addition, all recruited patients underwent mastectomy with or
without axillary lymphadenectomy, which would increase the
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tamoxifen-resistant cells. In the future, we would like to expand
the clinical research to include a large number of patients and a
long observation time to further conﬁrm the advantages of SHD
in creating a favorable microenvironment for adjuvant control of
breast cancer recurrence and metastasis.
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